Integrated Life Sciences Services
for Accelerated Innovation
We create a seamless pathway from concept to commercialization,
guiding your innovations through every stage of development.
Our in-house team provides integrated expertise in early discovery, advanced analytics, clinical trial planning, regulatory support and scalable manufacturing. By aligning these phases, we help bring your product to market faster and more efficiently.
API delivers an end-to-end experience with the right resources at the right time. Our wraparound services reduce costs and complexity while keeping your project moving. This holistic approach aligns science, strategy and execution—accelerating your path to market.
CDMO Services
We deliver flexible solutions for clinical and commercial manufacturing.
Discovery & Development
We create a seamless pathway from concept to commercialization, guiding your innovations through every stage of development.
Regulatory & Quality
We bridge the gap between academia and industry by providing the full expertise, services, and infrastructure of a life sciences company.
Clinical & Quantitative Solutions
We specialize in guiding companies through preclinical, clinical, and market safety phases, providing expert support at every stage of development.
Learn more about our services for different therapeutic areas
Pharmaceuticals & biologics
Discover how we can help you accelerate the drug development process.
Medical devices & diagnostics
Learn how we can help you navigate the intricacies of advanced medical technology.
Natural health products
Find out how we can empower your consistent NHP development.
Health technologies
See how we support the evolving landscape of health technologies.
Meet Our Executive Services Team
Sir Michael Houghton
Nobel Laureate & Chief Scientific Officer
Read bioabout Sir Michael Houghton Sir Michael Houghton
Nobel Laureate & Chief Scientific Officer
Dr. Michael Houghton was the Canadian Excellence Research Chair in Virology from 2010-2018 and is the Li Ka Shing Professor of Virology at the University of Alberta where he is also the Director of the Li Ka Shing Applied Virology Institute. He was jointly named the 2020 Nobel Prize winner in Physiology or Medicine along with Harvey J. Alter and Charles M. Rice in recognition of the discovery of the hepatitis C (HCV) virus. He was knighted by Queen Elizabeth II in 2020 for services to medicine. His research in the field of viral hepatitis has led to protection of the world’s blood supplies, and hepatitis C treatment to the point where the viral infection can now be cured in virtually all patients.
Launa Aspeslet
Chief Translational Officer
Read bioabout Launa Aspeslet Launa Aspeslet
Chief Translational Officer
Launa Aspeslet is an accomplished life science executive and board member with over 20 years of leadership experience in scaling early-stage organizations to sustainable growth and maturity. She excels in multi-stakeholder environments, new product development, and guiding entrepreneurs through organizational transformation.
Currently, Launa also serves as Senior Clinical & Regulatory Advisor to Model Medicines and a Board member of Edmonton Unlimited. She recently acted as interim CEO at Edmonton Unlimited and has held roles as COO at Hepion Pharmaceuticals, CEO of TRIO, and COO at Isotechnika Pharma. She has also provided strategic consulting for various early-stage drug and medical device companies. During this time, Launa has led teams to conduct over 50 clinical trials, enrolling more than 10,000 patients across 20 countries.
She holds a BSc in chemistry from the University of Lethbridge and a PhD in Pharmaceutical Sciences from the University of Alberta, along with a Regulatory Affairs Certification (RAC).
Allan Aginski
Senior VP, Special Projects & Manufacturing
Read bioabout Allan Aginski Allan Aginski
Senior VP, Special Projects & Manufacturing
Allan is a life sciences supply chain and manufacturing specialist with nearly 40 years of experience. He has established and run commercial life sciences company production facilities around the world, including for companies such as Abbott, Merck, and Genpharm. He has been responsible for the establishment of dozens of products in over 24 countries.
Hans Bauer
VP, Technical Operations
Read bioabout Hans Bauer Hans Bauer
VP, Technical Operations
Hans brings over 25 years of experience in pharmaceutical manufacturing and quality, having worked with leading pharmaceutical companies in Europe, including Lonza, Sandoz (Novartis), Acino, and Akorn. He has a proven track record in managing large teams, complex projects, and overseeing comprehensive operations.
Hans has strong expertise in developing and implementing robust quality systems that meet stringent regulatory standards across several countries, including the US, EU, and Switzerland. His production expertise includes API-small molecule manufacturing, peptide chemical and biotechnology manufacturing, as well as the production of solid and semi-solid forms and sterile manufacturing.
Located in one of Canada’s Fastest-Growing Life Sciences Hubs
Located in Edmonton, Alberta, API sits at the heart of one of Canada’s fastest-growing life sciences ecosystems. Our region is experiencing a surge in investment, with new infrastructure, expanded research capacity, and a strong pipeline of talent. Anchored by globally recognized institutions like the University of Alberta, Life Sciences Campus at the Edmonton Research Park and surrounded by a growing community of startups and a tightknit entrepreneur community, Edmonton offers a uniquely collaborative environment for innovation.
Edmonton is also a key part of the Canadian Critical Drug Initiative (CCDI), a nearly $200 million project led by our team at API in partnership with the University of Alberta. Through the CCDI, we’re developing an integrated research, commercialization and manufacturing cluster within the Edmonton Metropolitan Region.
As a Canadian-based CRO and CDMO, we also offer cost advantages and access to international markets—making us an ideal partner for both domestic and global companies looking to scale their therapeutic innovations.
The Canadian Critical Drug Initiative
Training & Programs for Life Sciences Innovators
Here are more resources to get your ideas to market.
In addition to services for the life sciences industry, API has a suite of programs and training resources for innovators looking to commercialize their ideas. Whether you’re looking for an incubator, network, or support and training for your business, check out our programs & training hub.
See all programs
Ready to take your life sciences innovation to the next level?
Contact us today for a free discovery consultation to determine how we can bring your idea to market together.
Get in touch